Efficacy and Safety of Biosimilar Ranibizumab (OPTIMAB®) versus Innovator Ranibizumab in Patients with Neovascular (Wet) Age-Related Macular Degeneration: A Double-Blind, Randomized, Multicenter, Phase III Study
Biosimilar ranibizumab (OPTIMAB<sup>®</sup>) was non-inferior to innovator ranibizumab in terms of efficacy, safety, and immunogenicity in the patients of nAMD.
Authors
- Deepika Singhal (ORCID: https://orcid.org/0000-0003-3285-4249)
- Pooja H Vaidya
- Vinod Kumar (ORCID: https://orcid.org/0000-0002-0086-7398)
- Sanghamitra Kanungo (ORCID: https://orcid.org/0009-0001-6861-2957)
- Dattatray Pawar
- Ajitkumar Gondane
- Urmil Shah (ORCID: https://orcid.org/0000-0002-7812-9678)
- Santosh Kumar Mahapatra (ORCID: https://orcid.org/0000-0001-7370-3995)
- Akhilesh Sharma
- Vinayaka Shahavi
- Mukesh K. Jaiswal
- Parth Rana
- Himanshu Deshmukh
- Harish Shandilya
- Ira Vakharia
Institutions
- Aditya Jyot Eye Hospital (IN)
- Sri Sri University (IN)
- Sardar Vallabhbhai National Institute of Technology Surat (IN)
- Vision Eye Institute (AU)
- Raghudeep Eye Hospital (IN)
- Hi Tech BioSciences India (India) (IN)
- Nethradhama Superspeciality Eye Hospital (IN)
- Vasan Eye Care Hospital (IN)
- Alkem (India) (IN)
- All India Institute of Medical Sciences (IN)
- B.J. Medical College (IN)
Publication Details
- Journal
- Clinical ophthalmology
- Published
- 2024-10-01
- DOI
- https://doi.org/10.2147/opth.s488866
- Citations
- 5
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.69